TY  - JOUR
AU  - Roboz, Gail J
AU  - Montesinos, Pau
AU  - Selleslag, Dominik
AU  - Wei, Andrew
AU  - Jang, Jun-Ho
AU  - Falantes, Jose
AU  - Voso, Maria T
AU  - Sayar, Hamid
AU  - Porkka, Kimmo
AU  - Marlton, Paula
AU  - Almeida, Antonio
AU  - Mohan, Sanjay
AU  - Ravandi, Farhad
AU  - Garcia-Manero, Guillermo
AU  - Skikne, Barry
AU  - Kantarjian, Hagop
PY  - 2016
DO  - 10.2217/fon.15.326
UR  - http://hdl.handle.net/10668/9745
T2  - Future oncology (London, England)
AB  - Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in...
LA  - en
KW  - CC-486
KW  - Phase III
KW  - acute myeloid leukemia
KW  - de novo
KW  - elderly
KW  - maintenance therapy
KW  - oral azacitidine
KW  - secondary
KW  - Administration, Oral
KW  - Antimetabolites, Antineoplastic
KW  - Azacitidine
KW  - Clinical Trials, Phase III as Topic
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - Maintenance Chemotherapy
KW  - Middle Aged
KW  - Randomized Controlled Trials as Topic
TI  - Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
TY  - research article
VL  - 12
ER  -